Brokers Offer Predictions for Zafgen, Inc.’s FY2017 Earnings (ZFGN)
Zafgen, Inc. (NASDAQ:ZFGN) – Analysts at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for Zafgen in a research note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings per share of ($2.02) for the year, up from their prior estimate of ($2.10). Leerink Swann also issued estimates for Zafgen’s FY2018 earnings at ($1.35) EPS and FY2019 earnings at ($1.11) EPS.
A number of other research firms also recently issued reports on ZFGN. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $6.63.
Shares of Zafgen (ZFGN) opened at $3.69 on Friday. Zafgen has a 52-week low of $3.11 and a 52-week high of $5.46.
Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.12.
In related news, Director Frances K. Heller purchased 10,000 shares of Zafgen stock in a transaction dated Friday, October 13th. The stock was bought at an average cost of $3.90 per share, for a total transaction of $39,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 21.20% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its position in shares of Zafgen by 44.7% in the first quarter. Dimensional Fund Advisors LP now owns 443,311 shares of the biopharmaceutical company’s stock valued at $2,066,000 after purchasing an additional 136,849 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Zafgen by 1,290.3% in the first quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 40,400 shares in the last quarter. LMR Partners LLP purchased a new position in shares of Zafgen in the second quarter valued at $299,000. Bank of New York Mellon Corp grew its position in shares of Zafgen by 5.9% in the first quarter. Bank of New York Mellon Corp now owns 104,199 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 5,794 shares in the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in shares of Zafgen in the second quarter valued at $364,000. Institutional investors own 48.52% of the company’s stock.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.